Beta-blockers and RAAS inhibitors may prevent LVEF dysfunction due to breast cancer drugs: Study
Sweden: A meta-analysis suggests that beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) may help in preserving LVEF in women undergoing breast cancer treatment with trastuzumab and/or anthracyclines. The study appears in the European Heart Journal.
Trastuzumab and anthracyclines are used often for the treatment of breast cancer. However, its use may impair myocardial function and reduce left ventricular ejection fraction (LVEF), potentially causing heart failure. Randomized controlled trials (RCTs) have evaluated the effects of BBs, ACEI/ARBs on trastuzumab- and anthracycline-associated cardiotoxicity.
Considering the above, Christian Lewinter, Heart Centre, Karolinska University Hospital, Karolinska Universitetssjukhuset Solna, Solna, Stockholm, Sweden, and colleagues aimed to assess the effect of BBs and ACEI/ARBs on LVEF in patients treated with either trastuzumab, anthracyclines, or both by conducting a meta-analysis of the RCTs in patients with breast cancer.
The researchers conducted primary and secondary analyses. The primary analysis was on the effect of BBs and ACEI/ARBs on LVEF in patients treated with either trastuzumab or anthracyclines. Secondary analysis was done investigating the effect of BBs or ACEI/ARBs on LVEF in trastuzumab and anthracycline treatments. Meta-analysis was conducted to estimate the mean difference (MD) in LVEF between intervention and placebo groups at follow-up.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.